Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b proof-of-concept study of diltiazem plus standard care in hospitalized patients with COVID-19 pneumonia
2021-004160-94Phase 2Terminated
- Sponsor
- Hospices Civils de Lyon
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia comparing Standard care + diltiazem with Standard care + placebo (2 arms). Primary endpoint: Change in SARS-CoV-2 viral load from day 1 to day 7. Started Jan 2022; status: terminated.
02
Drugs
diltiazem
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on 2021-004160-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004160-94.